Company intelligence / Profile preview

Apextide

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Apextide is an active, China-based contract development and manufacturing organization (CDMO) specializing in peptides, oligonucleotides, and small molecule drugs. The company provides comprehensive R&D and manufacturing services to global biopharmaceutical companies. It has over 20 years of experience through its parent company Sinopep Biotech. Recent regulatory milestones include FDA acknowledgment of its Drug Master File submission for inclisiran API. Its product catalog includes complex peptide APIs such as goserelin, atosiban, exendin, albiglutide, thymopentin, nesiritide acetate, secretin acetate, icatibant acetate, pasireotide, vapreotide acetate among others.

Modalities: PeptidesOligonucleotidesSmall molecule drugsBiologic (for peptide/oligonucleotide APIs)
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Apextide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apextide.

Explore the full profile